SPRO logo

SPROSpero Therapeutics Inc

$2.85
$0.135
(4.53%)
Today
Updated: 12:43 PM EDT
Reported EarningsMay 13
Mkt Cap$172.55M
Vol395,057.00
62

Bullish Sentiment

How do you feel about SPRO?

News
all
press releases
Compass Pathways Elects Kathleen Tregoning to Board of Directors
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected...
Business Wire
News Placeholder
More News
News Placeholder
Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Significant Growth in Short Interest
Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 737,720...
MarketBeat
News Placeholder
GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth
GSK Q1 earnings and revenues beat estimates as Specialty Medicines lifted sales, with HIV, oncology and respiratory growth. The guidance for 2026 remains unchanged.
Zacks
News Placeholder
Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Above 50 Day Moving Average - What's Next?
Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 50-Day Moving Average - Here's What Happened...
MarketBeat
News Placeholder
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Above 50-Day Moving Average - Time to Sell?
Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above Fifty Day Moving Average - Should You Sell...
MarketBeat
News Placeholder
Spero Therapeutics (NASDAQ:SPRO) Upgraded by Wall Street Zen to "Strong-Buy" Rating
Wall Street Zen raised shares of Spero Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Sunday...
MarketBeat
News Placeholder
Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Beats Estimates By $0.73 EPS
Spero Therapeutics (NASDAQ:SPRO - Get Free Report) released its quarterly earnings results on Thursday. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts...
MarketBeat
News Placeholder
Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to "Hold"
Wall Street Zen lowered shares of Spero Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday...
MarketBeat
News Placeholder
Spero Therapeutics (SPRO) Expected to Announce Earnings on Thursday
Spero Therapeutics (NASDAQ:SPRO) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-26-spero-therapeutics-inc-stock...
MarketBeat
News Placeholder
Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Large Decline in Short Interest
Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) was the target of a large decrease in short interest in February. As of February 27th, there was short interest totaling 574,027 shares, a...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.